| Anti-inflammatory agents | Aspirin | Especially doses > 2.7 g per day |
| Nonsteroidal anti-inflammatory drugs | All agents implicated |
| Sulfasalazine (Azulfidine) | — |
| Antimalarial agents | Quinine and chloroquine (Aralen) | — |
| Antimicrobial agents | Aminoglycosides | Tinnitus usually is an initial sign of ototoxicity, often with rapid progression to hearing loss; hearing loss or tinnitus that persists two to three weeks after discontinuing the drug is likely permanent |
| Macrolides | Erythromycin: rare at dosages < 2 g per day |
| Tetracyclines: doxycycline, minocycline (Minocin) | Higher risk in women; symptom onset one to three days after initiation of therapy |
| Vancomycin | Rare if not used with other ototoxic agents |
| Other anti-infectives: imipenem/cilastatin (Primaxin), linezolid (Zyvox), sulfonamides, fluoroquinolones, voriconazole (Vfend), amphotericin B, ganciclovir (Cytovene), ribavirin (Rebetol) | — |
| Antineoplastic agents | Vinca alkaloids, etoposide, protein kinase inhibitors, platinum derivatives | — |
| Loop diuretics | All agents implicated | Highest risk with high doses and/or rapid infusions |
| Miscellaneous agents | Antiarrhythmics, anticonvulsants, antihypertensives, antiulcer drugs, hormones, psychotropic drugs, atorvastatin (Lipitor), bupropion (Wellbutrin), risedronate (Actonel), varenicline (Chantix) | — |
| Regional anesthetics | Lidocaine (Xylocaine), bupivacaine (Marcaine) | — |
| Topical agents | Topical otic preparations containing ototoxic drugs | — |
